Significant Shareholder Atlas Venture Files Intent to Sell $3.08M in KYMR Stock
KYMR has more than doubled off its 52-week low of $36.65 on elevated volume (4.7× avg).
Summary
Atlas Venture Opportunity Fund I, LP, a significant institutional shareholder, has filed a Form 144 indicating its intent to sell approximately $3.08 million in Kymera Therapeutics common stock, continuing a pattern of distribution from the venture firm.
Key Events · Ownership and Investor Activity · KYMR
-
Intent to Sell Shares
Atlas Venture Opportunity Fund I, LP has filed a Form 144 indicating its intent to sell 34,152 shares of common stock, valued at approximately $3.08 million.
-
Ongoing Shareholder Distribution
This proposed sale is part of a broader distribution trend, with Atlas Venture entities having sold approximately $22.4 million worth of shares over the past three months.
-
Significant Institutional Filer
Atlas Venture is a significant institutional shareholder, and their continued selling could be interpreted as a lack of conviction or a move to rebalance their portfolio.
Analysis · KYMR · Life Sciences
This Form 144 signals a continued distribution of shares by Atlas Venture, a significant institutional investor in Kymera Therapeutics. While the current proposed sale of $3.08 million is modest relative to the company's market cap, it adds to over $22 million in sales by Atlas Venture entities over the past three months. This ongoing selling by a major shareholder could create an overhang on the stock, despite recent positive clinical and financial news from the company.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.1% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KYMR was trading at $99.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $36.65 to $105.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.